Trials / Completed
CompletedNCT02811731
Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers (B)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the safety and pharmacokinetics of CKD-330 (fixed-dose combination of Candesartan 16 mg and Amlodipine 5 mg) with coadministration of the two separate drugs in healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-330 16/5mg - B | |
| DRUG | Candesartan 16mg and Amlodipine 5mg |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2015-05-01
- Completion
- 2015-08-01
- First posted
- 2016-06-23
- Last updated
- 2016-06-23
Source: ClinicalTrials.gov record NCT02811731. Inclusion in this directory is not an endorsement.